A new study reports a beneficial effect of avenciguat — a novel, nitric oxide (NO)-independent, soluble guanylate cyclase (sGC) activator — on albuminuria in patients with chronic kidney disease (CKD). These findings were presented at the 61st European Renal Association Congress in Stockholm.
In patients with CKD, insufficient production of NO leads to impairment of NO–sGC–cyclic guanosine monophosphate signalling in the kidney, resulting in endothelial dysfunction and an increased risk of disease progression. Avenciguat was developed with the aim of restoring endothelial function and thereby slowing loss of kidney function and reducing the risk of cardiovascular disease in patients with CKD.
- The Renal Warrior Project. Join Now
- Source: https://www.nature.com/articles/s41581-024-00866-6